DESTINY-Breast05 delivers definitive head-to-head data — pitting T-DXd against T-DM1 in the adjuvant setting for residual HER2+ disease. Drs. Pegram and Iyengar discuss recurrence-free survival gains and reduced CNS relapse rates that may redefine adjuvant therapy.
Adjuvant ADC Head-to-Head: DB05 Data Define a New Standard in Early HER2-Positive Breast Cancer
You may also like
Recommended Videos
